Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
STP908
- Development stage
- Preclinical
- Lead developer
- Sirnaomics
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
STP908 is an investigational RNA interference (RNAi) therapeutic developed by Sirnaomics, designed for the treatment of liver-related diseases including liver fibrosis and hepatocellular carcinoma (HCC). It utilizes the company proprietary GalAhead platform, specifically the muRNA (multi-unit RNA) technology, which enables the simultaneous silencing of two distinct genetic targets within a single therapeutic entity. STP908 targets transforming growth factor-beta 1 (TGF-β1) and cyclooxygenase-2 (COX-2), both of which are critical mediators of inflammation and fibrogenesis in the liver. The molecule is conjugated with N-acetylgalactosamine (GalNAc) to facilitate targeted delivery to hepatocytes via the asialoglycoprotein receptor (ASGPR). This liver-specific delivery mechanism is intended to enhance therapeutic potency while minimizing systemic exposure and potential off-target effects.
- Other names
- GalNAc-TGF-beta1/COX-2 siRNAGalAhead-muRNA-TGF-beta1/COX-2
02
Targets
SARS-CoV-2 N (SARS-CoV-2 N protein)SARS-CoV-2 gRNA (SARS-CoV-2 genomic RNA)
Beyond the preview
Go deeper on STP908.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on STP908.